The Open Source software movement has broken the stranglehold of expensive, proprietary products. Could the same thing happen in biotechnology?

Advances in neuroscience are opening up the treatment options for central nervous system diseases - at the same time as the ageing population is increasing the market for these products.

Microsoft Corp. is spinning out some of its software technology to two small European tech ventures, as part of a program to speed development of innovations from its labs.

Fujeribio Diagnostics, Inc., based in Japan, has bought Swedish CanAg Diagnostics, merging two leading biotechnology companies in cancer diagnosis.

A team of researchers at ORNL has come up with the concept of nanofermentation, and, it seems, plans to use this as a trademark.

Europabio thinks that Europe is doing a poor job when it comes to investing in biotechnology.

On May 26, the US Patent Office issued a preliminary ruling on another long-running patent fight. This battle differs from other high-profile clashes as the challenger is taking on not a big corporate entity, but a broad community of IT researchers and academics.

EU technology policy is moving beyond the numbers game, and getting down to economic basics.

With global revenues of $110 billion last year, and an aging population, the nascent "neurotechnology" market appears poised for huge growth.

The European Commission wants businesses to spend more on research and development - and to help encourage that, the agency is preparing a volley of government proposals for the Autumn.